Patent Oppositions in infection drugs industry

Explore the competitive field of infection drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in infection drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the infection drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the infection drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Oct 1, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Compositions Comprising 2 -Fucosyllactose To Prevent Viral InfectionsFRIESLANDCAMPINA NEDERLANDSep 16, 2026NESTLE
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 10, 2026CAMULON
Compositions Comprising 2 -Fucosyllactose To Prevent Viral InfectionsFRIESLANDCAMPINA NEDERLANDSep 9, 2026DMK DEUTSCHES MILCHKONTOR
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 9, 2026LEPTHIEN
Formulation For Anti-Alpha4Beta7 AntibodyMILLENNIUM PHARMACEUTICALSSep 4, 2026ABEL & IMRAY
Method And Compositions For Inducing Differentiation Of Myeloid Derived Suppressor Cell To Treat Cancer And Infectious DiseasesOSE IMMUNOTHERAPEUTICSSep 3, 2026STRAWMAN
Bi-Layer Pharmaceutical Tablet FormulationVIIV HEALTHCAREAug 26, 2026CAMULON
Compositions Comprising 2 -Fucosyllactose To Prevent Viral InfectionsFRIESLANDCAMPINA NEDERLANDAug 21, 2026ABBOTT LABORATORIES
A Method For High Level And Stable Gene Transfer In LymphocytesJULIUS MAXIMILIANS UNIVERSITT WRZBURGJul 3, 2026MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ GEMEINSCHAFT
Biphenyl Sulfonamide Compounds For The Treatment Of Type Iv Collagen DiseasesTRAVERE THERAPEUTICSJun 30, 2026TEVA PHARMACEUTICAL INDUSTRIES LTD

To stay ahead in the competitive infection drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the infection drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Oct 1, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Sep 17, 2025Methods Of Treating Chronic Kidney Disease With DapagliflozinASTRAZENECA14
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE10
Sep 25, 2024Nucleoside Phosphoramidate ProdrugsPHARMASSET10
Jan 25, 2017Use Of DaptomycinCUBIST PHARMACEUTICALS7
Aug 24, 2022Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses ThereofE R SQUIBB & SONS6
Mar 4, 2015Unitary Pharmaceutical Dosage Form Comprising Tenofovir DfGILEAD SCIENCES5
Mar 14, 2018Crystalline Form Of Abacavir That Is Essentially Free Of SolventESTEVE QUMICA5
Dec 4, 2024Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-OlateGILEAD SCIENCES5
Oct 23, 2024Modified Fluorinated Nucleoside AnaloguesGILEAD PHARMASSET4
Mar 18, 2015Crystalline Form Of Abacavir That Is Essentially Free Of SolventESTEVE QUMICA4